INS and type 1 diabetes mellitus: Although several aspects of insulin pump therapy may contribute to improved glycemic outcomes, one may argue that the required pump site change at 72 h with this tubeless insulin pump system may potentially alleviate some of the infusion site issues that contribute to hyperglycemia and the increased potential for DKA.40,43 Of note, the frequency of DKA of 2.2% in this study compares favorably with the frequency of DKA reported for insulin pump users overall from the U.S. T1D Exchange (T1DX) registry (5.2% [4] and the German/Austrian DPV registry (3.4% [(3] to 5.2%).4